1. Bone RC. Gram-negative sepsis. Background, clinical features, and intervention. Chest. 1991;100:802-8.
2. Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457-69.
3. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;136:1644-55.
4. Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112:235-43.
5. Besirbellioglu BA. EKMUD Bilimsel Platformu. Bilkent Otel ve Konferans Merkezi: Ankara; 2006. Hayatı tehdit eden enfeksiyonların tedavisi: Sepsis.
6. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a
7. critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23:1430-9.
8. Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885-91.
9. Cheng B, Hoeft AH, Book M, Shu Q, Pastores SM. Sepsis: pathogenesis, biomarkers, and treatment. Biomed Res Int. 2015;2015:846935.
10. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-73.
11. Hadley JS, Hinds CJ. Anabolic strategies in critical illness. Curr Opin Pharmacol. 2002;2:700-7.
12. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-50.
13. Medzhitov R, Janeway C., Jr Innate immunity. N Engl J Med. 2000;343:338-44.
14. Marx G, Schuerholz T, Reinhart K. New approaches to intensive care for sepsis. Chirurg. 2005;76:845-55.
15. Mertens K. Applied Biology. University of Aberdeen.; 2014. Zinc in inflammation and sepsis.
16. Mermutluoglu C, Deveci O, Dayan S, Aslan E, Bozkurt F, Tekin R. Antifungal susceptibility and risk factors in patients with candidemia. Eurasian J Med. 2016;48:199-203.
17. Nguyen HB, Rivers FM, Abrahamian, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med. 2006;48:28-54.
18. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis. 1997;24:1068-78.
19. Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699-713.
20. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776-87
21. Sriskandan S, Cohen J. The pathogenesis of septic shock. J Infect. 1995;30:201-6.
22. Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536-45.
23. Sahin S. Klinik Bakteriyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı. Erciyes Üniversitesi Tıp Fakültesi; 2009. Sepsiste Suprafizyolojik Doz Steroid Tedavisinin Yeri.
24. Tas G. Askeri Tıp Fakültesi İç Hastalıkları Bilim Dalı Başkanlığı. T.C. Genelkurmay Başkanlığı Gülhane Askeri Tıp Akademisi; 2010. Deneysel Rat Sepsis Modelinde Fenofibrat Tedavisinin Rolü
25. Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med. 2003;31:359-66.
26. Wang H, Bloom O, Zhang M, et al. HMG- 1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-51
Bone RC. Gram-negative sepsis. Background, clinical features, and intervention. Chest. 1991;100:802-8.
Bone RC. The pathogenesis of sepsis. Ann Intern Med. 1991;115:457-69.
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;136:1644-55.
Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997;112:235-43.
Besirbellioglu BA. EKMUD Bilimsel Platformu. Bilkent Otel ve Konferans Merkezi: Ankara; 2006. Hayatı tehdit eden enfeksiyonların tedavisi: Sepsis.
Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23:1430-9.
Cohen J. The immunopathogenesis of sepsis. Nature. 2002;420:885-91.
Cheng B, Hoeft AH, Book M, Shu Q, Pastores SM. Sepsis: pathogenesis, biomarkers, and treatment. Biomed Res Int. 2015;2015:846935.
Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-73.
Hadley JS, Hinds CJ. Anabolic strategies in critical illness. Curr Opin Pharmacol. 2002;2:700-7.
Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:138-50.
Medzhitov R, Janeway C., Jr Innate immunity. N Engl J Med. 2000;343:338-44.
Marx G, Schuerholz T, Reinhart K. New approaches to intensive care for sepsis. Chirurg. 2005;76:845-55.
Mertens K. Applied Biology. University of Aberdeen.; 2014. Zinc in inflammation and sepsis.
Mermutluoglu C, Deveci O, Dayan S, Aslan E, Bozkurt F, Tekin R. Antifungal susceptibility and risk factors in patients with candidemia. Eurasian J Med. 2016;48:199-203.
Nguyen HB, Rivers FM, Abrahamian, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med. 2006;48:28-54.
Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis. 1997;24:1068-78.
Russell JA. Management of sepsis. N Engl J Med. 2006;355:1699-713.
Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776-87
Sriskandan S, Cohen J. The pathogenesis of septic shock. J Infect. 1995;30:201-6.
Schouten M, Wiersinga WJ, Levi M, van der Poll T. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol. 2008;83:536-45.
Sahin S. Klinik Bakteriyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı. Erciyes Ãœniversitesi Tıp Fakültesi; 2009. Sepsiste Suprafizyolojik Doz Steroid Tedavisinin Yeri.
Tas G. Askeri Tıp Fakültesi İç Hastalıkları Bilim Dalı BaÅŸkanlığı. T.C. Genelkurmay BaÅŸkanlığı Gülhane Askeri Tıp Akademisi; 2010. Deneysel Rat Sepsis Modelinde Fenofibrat Tedavisinin Rolü
Van den Berghe G, Wouters PJ, Bouillon R, et al. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med. 2003;31:359-66.
Wang H, Bloom O, Zhang M, et al. HMG- 1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-51
